Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-867-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Based on the molecular weight (386.67 g/mol), low particle size (mass median diameter < 2.8 µm), high water solubility (36.4 g/L), very low log Kow (-2.9) and very low vapour pressure (2.25 E-11 kPa at 25°C), it can be expected that both oral and respiratory absorption rates are moderate and dermal absorption is low. The adverse effects of the 28-day oral repeated dose gavage toxicity study confirm the moderate oral absorption rate.
Distribution in the body cells is not expected to be wide based on the lipophobic character and the elimination of the product will mainly occur through the bile.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 5
- Absorption rate - inhalation (%):
- 50
Additional information
Toxicokinetic assessment of T002102
T002102 (CAS 179108-06-6), is a powder with a moderate molecular weight (386.67 g/mol), a low particle size (mass median diameter < 2.8 µm), a high water solubility (36.4 g/L), a very low log Kow (-2.9) and a very low vapour pressure (2.25 E-11 kPa at 25°C). The substance is not found to be irritating to the skin.
The backbone of T002102 is a benzazepine group which contains a benzene ring and an azepine group (a heterocyclic ring structure with 1 nitrogen and 6 carbon atoms), substituted by a cyclohexenone and furan group, a bromine and a methoxy functional group. The structure is also hydrogenated. T002102 resembles the commercially available alkaloid called galantamine, but with a carbonyl instead of a hydroxyl functional group and a bromine attached to the benzyl group. T002102 is a racemic mixture and a hydrochloric salt.
No toxicokinetic data (animal or human studies) are available on this substance. The data present in this dossier are based on physico-chemical and toxicological parameters and will allow a qualitative assessment of the toxicokinetic behaviour of T002102.
Absorption
Oral/GI absorption:
T002102 is a watersoluble molecule which will readily dissolve into the gastrointestinal (GI) fluids through the aqueous pores or through carriage across membranes (epithelial barrier) with the bulk passage of water (passive diffusion). The predominant site of absorption along the gastrointestinal tract is the small intestine through passive diffusion.
A 28-day repeated oral gavage toxicity study (Braun et al., 2002) has been performed with T002102. Rats were exposed to 10, 50, 200 mg/kg/day (nominal concentrations) which indicated that salivation occurred at high dose level in some males. Test substance-related findings in the clinical biochemistry parameters of males and females treated with 200 mg/kg/day (nominal concentration) indicated minor changes in lipid metabolism. Increased liver weights were observed in males and females treated with 200 mg/kg/day (nominal concentration), and test substance-related microscopic findings in the liver (minimal centrilobular hypertrophy) and thyroid gland (follicular cell hypertrophy) were noticed in males and females at 200 mg/kg/day (nominal concentration). This indicates T002102 is absorbed after oral exposure and reaches the liver and thyroid gland. The NOAEL and NOEL were considered to be 41.85 mg/kg/day (50 mg/kg/day nominal concentration corrected based on analytical verification results).
The results of a reproductive/developmental toxicity screening test of T002102 in rats by oral gavage according with dose levels of 11, 55 or 165 mg/kg/day (or 10, 50, 150 mg eq/kg/day) (Peter, 2016) revealed parental toxicity at 165 mg/kg/day in male rats (lower epididymides organ weights, histopathological changes in testes and epididymides). Reproductive toxicity was observed in female rats at 165 mg/kg/day and attributed to the adverse effect of the test item on male fertility. Furthermore, developmental toxicity was noticed at the dose level of 55 mg/kg/day.
T002102 was found to be hydrolytically stable at pH 4.0 (estimated half-life of about 200 days at 50°C), not stable at pH 7.0 (estimated half-life of 187 hours (8 days) at 25°C). For that reason, only limited degradation of the substance is expected in the gastro-intestinal tract (pH 2-8).
The oral absorption factor is set to 50%, based on the physicochemical properties and the results of the toxicity studies.
Respiratory absorption:
Given the low vapour pressure of 2.25 E-11 kPa, T002102 is not considered to be a volatile substance and the availability for inhalation as a vapour is limited. However, the product is can be considered as a dust with a mass median diameter of 2.8 µm, so inhalation is expected. There is no information on the aerodynamic diameter of the product, so no information on the deposition within the respiratory tract can be derived.
In case the substance ends up in the respiratory tract, T002102 can diffuse/dissolve into the mucus lining the respiratory tract, since it is a fine water soluble powder. However its lipophobic character implies that the product won’t be absorbed directly across the respiratory tract epithelium through passive diffusion. Based on its moderate molecular weight (MW>200), it can be predicted that the substance will not be absorbed through aqueous pores, but be retained in the mucus and transported out of the respiratory tract. However, the oral toxicity study described above (Braun et al., 2002) showed that there are signs of systemic toxicity, indicating absorption after ingestion so some absorption after inhalation can be expected. The respiratory absorption factor is set to 50%.
Dermal absorption:
T002102 is a solid substance and therefore the product is not readily taken up by the skin in comparison to liquid products. The dry product will have to dissolve into the surface moisture of the skin before uptake can take place. Based on its high water solubility (36.4 g/L) and its low log Kow value (< 0), the substance is probably too hydrophilic to cross the lipid rich environment of the stratum corneum.An acute dermal toxicity study in rats (Damme, 2001) with a fixed dose of 2000 mg/kg showed no systemic or local toxicity effects during the study period of 2 weeks. Furthermore, the product is notskin irritant or skin corrosive. Based on the physicochemical parameters and the toxicity data, it can be concluded that dermal uptake of T002102 will be low. As a result, the dermal absorption factor for T002102 is set to 5%.
Distribution
The high water solubility and moderate molecular weight predict that T002102 will probably distribute through the body due to diffusion through aqueous channels and pores. Since the substance is not lipophilic, it won’t distribute much into cells. Therefore, in fatty tissues, the extracellular concentration of the substance will be higher than the intracellular concentration. On the other hand,based on the 28-day repeated oral gavage toxicity study described above, the product distributes to the thyroid gland and liver after ingestion.
Accumulation
Since T002102 is a very water soluble and hydrophilic substance, no (or little) accumulation is expected within the body (lung, adipose tissue, stratum corneum).
Metabolism
Once absorbed, T002102 might undergo phase I biotransformation (including reduction, hydroxylation) followed byconjugation reactions (phase II) such as glucuronidation and sulfation.
Excretion
Given the moderate molecular weight (Mw>300), T002102 and its metabolites (such as conjugated glucuronides) will most likely actively be excreted through the bile. Substances in the bile pass through the intestines before they are excreted in the feces and thus may undergo enterohepatic recycling which will prolong their biological half-life.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.